3 Key Takeaways From Medtronic’s Earnings

What three major lessons can investors learn from Medtronic’s fourth-quarter earnings report?

May 21, 2014 at 10:10AM

Medtronic (NYSE:MDT) investors received a double dose of bad news on Tuesday: The medical device maker missed top-line estimates for the fourth quarter, then reported a big hit to its bottom line after reaching a patent settlement with rival Edwards Lifesciences (NYSE:EW). Shares slumped slightly, continuing Medtronic's yearlong trend of underperforming industry peers St. Jude Medical and Boston Scientific.

MDT Chart

Source: Ycharts.

During the fourth quarter, Medtronic's revenue rose 2% year over year to $4.57 billion, but missed the consensus estimate by $10 million. Medtronic's generally accepted accounting principles-adjusted earnings fell 54% year over year to $0.44 per share, due to the patent settlement with Edwards Lifesciences and a product liability settlement. On a non-GAAP basis, earnings rose 2% year over year to $1.12 per share, matching the analyst estimate.

Let's look at three key takeaways from the first-quarter earnings to better gauge Medtronic's quality as an investment.

Cardiac growth remains slow but steady
Sales at Medtronic's cardiac and vascular group, its largest business segment, climbed 1% year over year to $2.4 billion.

Revenue from cardiac rhythm disease management, or CDRM, which includes its pacemakers and defibrillation systems, rose 1% to $1.4 billion. Medtronic reported strong international adoption of the Viva XT CRT-D pacemaker, which resynchronizes to the patient on a minute-to-minute basis. Medtronic also launched the world's only full-body MRI-compatible pacemaker, the Evera MRI, in Europe.

Medtronic's main rival in that market, St. Jude Medical, reported similar results last quarter -- sales of its cardiac rhythm management devices rose 1% to $687 million. Boston Scientific has fared worse than Medtronic and St. Jude, as sales at its cardiac rhythm segment fell 3% last quarter to $466 million.

Medtronic's structural heart revenue rose 9% year over year to $337 million, thanks to the U.S. launch of CoreValve, a self-expanding catheter system for severe aortic stenosis. However, following its patent settlement over the CoreValve, Medtronic must now pay quarterly royalty payments (at a minimum rate of $40 million annually) to Edwards Lifesciences through April 2022. Edwards will also receive a one-time payment of $750 million.

Medtronic trails Stryker in restorative therapies
Medtronic's second-largest business, its restorative therapies group, consists of spine, neuromodulation, and surgical technology products. First-quarter revenue in the segment climbed 2% year over year to $1.74 billion.

Medtronic's main competitor in these three fields is Stryker (NYSE:SYK). A comparison of the two companies shows that although Medtronic generates more revenue in each of the categories, Stryker is growing at a faster rate.


Medtronic revenue / growth

Stryker revenue / growth


$786 million / (3%)

$177 million / 0.7%

Neuromodulation / Neurotechnology

$513 million / 4%

$243 million / 10%

Surgical Technology

$438 million / 8%

$343 million / 10.1%

Sources: Company quarterly reports, all growth percentages as reported.

While Medtronic recently highlighted some impressive products from the three categories, including its Activa "brain pacemaker" and new tools for surgeons, these newer products haven't yet become major sources of sales growth. The results from Medtronic and Stryker also show that demand for surgical technology and neurotechnology is outpacing demand for spinal products by a wide margin.

Medtronic's diabetes group is its fastest-growing business
Medtronic's diabetes group, its smallest business segment, reported robust revenue growth during the quarter, thanks to strong demand for the MiniMed 530G with Enlite CGM (constant glucose monitoring) sensor -- a self-regulating insulin pump system dubbed as the first "wearable artificial pancreas".

The MiniMed 530G system, which the FDA approved last October, automatically shuts off insulin delivery if a user's glucose level falls below a certain threshold. Since the launch of the MiniMed 530G with Enlite CGM, Medtronic estimates that it has gained over 5 percentage points in the U.S. insulin pump market and over 6 percentage points of the U.S. CGM market.

Revenue at Medtronic's diabetes group rose 13% year over year to $460 million, making it the company's fastest-growing business. However, investors should note that Johnson & Johnson's Animas division and Dexcom have developed a competing product, the Animas Vibe, which could be approved by the FDA later this year.

The Foolish takeaway
Medtronic is a mixed bag as an investment. Although it has some highly innovative products in its portfolio, its slower-growth businesses tend to offset its higher-growth units.

Medtronic has kept its CRDM business growing at a healthy rate, even as smaller rivals such as Boston Scientific have fallen behind. However, Medtronic still trails Stryker's growth rate in spinal care, neurotechnology, and surgical tech. Meanwhile, Medtronic's diabetes business has posted impressive growth, but it's unclear if the company can maintain that momentum once the Animas Vibe hits the market.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Leo Sun has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers